<DOC>
	<DOCNO>NCT01774773</DOCNO>
	<brief_summary>E5501 ( 5 mg , 20 mg , 40 mg ) administer healthy male adult single-center , randomize , open-label , cross-over manner . This study consist 2 phase include pre-randomization ( drug administration ) postrandomization ( drug administration ) .</brief_summary>
	<brief_title>A Single-dose Study Healthy Japanese Male Adults Evaluate Pharmacokinetics Pharmacodynamics E5501 5 mg Tablet ( Study E5501-J081-015 )</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion ; 1 . Nonsmokers age 2044 time inform consent , 2 . BMI 18.5 kg/m2 25 kg/m2 screening , 3 . Platelet count 120,000/ microliter 300,000/ microliter screen baseline 4 . Subjects partner agree use medically appropriate contraception study period 5 . Voluntarily provide write informed consent 6 . Willing able comply protocol Exclusion criterion ; 1 . With past present history arterial thrombosis , venous thrombosis thrombophilia 2 . With past history clinically significant disease within 8 week study drug administration clinically significant infection within 4 week study drug administration 3 . With past surgical history may affect pharmacokinetics E5501 4 . Suspected clinically abnormal symptom organ dysfunction require treatment base past history , complication , subjective objective symptom , vital sign body weight , electrocardiograms clinical laboratory result screen baseline 5 . QTcF great 450 m ( correct heart rate accord Fridericia 's formula ) category 12lead electrocardiogram screening baseline</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>